■印度尼西亚目前建议使用灭活的SARS-CoV-2疫苗(CoronaVac)进行异源引发,并使用基于mRNA的COVID-19疫苗(Moderna或Pfizer)进行加强。这些异源疫苗方案的反应原性数据并不完全可用,尤其是年轻人。本研究,因此,目的是评估在接受两剂CoronaVac的先前接受者接种Moderna或Pfizer疫苗后的前7天,征求的局部和全身反应。
■在PelitaHarapan大学的医学生中进行了一项基于电子的横断面研究,万丹,印度尼西亚,他在两剂CoronaVac后接受了基于mRNA的COVID-19疫苗。使用整群抽样技术收集样品。组间比较采用Fisher精确检验。
■共有72名参与者,其中23人(32%)接受了Moderna疫苗,49人(68%)接受了辉瑞疫苗,包括在这项研究中。参与者的平均年龄为21岁(IQR19-22岁)。基于mRNA的COVID-19疫苗最常见的局部和全身事件是注射部位疼痛,发烧,头痛,疲劳,肌痛,和关节痛.与辉瑞接受者相比,Moderna接受者报告的局部和全身反应更为频繁。大多数局部和全身反应被分级为轻度至中度,并且不会导致住院。
■在年轻人中使用CoronaVac和基于mRNA的COVID-19疫苗加强剂的异源初免反应原性令人放心,没有发现意外的担忧。
UNASSIGNED: Heterologous priming with the inactivated SARS-CoV-2 vaccine (CoronaVac) and boosting with mRNA-based COVID-19 vaccine (Moderna or Pfizer) is currently recommended in Indonesia. The reactogenicity data of these heterologous vaccine regimens are not entirely available, particularly in young adults. The present study, therefore, aimed to evaluate the solicited local and systemic reactions in the first seven days post-vaccination either with Moderna or Pfizer vaccine among previous recipients of two doses of CoronaVac.
UNASSIGNED: An electronic-based cross-sectional study was conducted among medical students at the Pelita Harapan University, Banten, Indonesia, who received mRNA-based COVID-19 vaccine following two doses of CoronaVac. Samples were collected using a cluster sampling technique. Comparison between groups was performed by Fisher\'s exact test.
UNASSIGNED: A total of 72 participants, 23 (32%) of which received the Moderna vaccine and 49 (68%) received the Pfizer vaccine, were included in this study. The median age of participants was 21 (IQR 19-22) years old. The most common local and systemic events for mRNA-based COVID-19 vaccines were injection site pain, fever, headache, fatigue, myalgia, and arthralgia. Solicited local and systemic reactions were reported more frequently in Moderna recipients than Pfizer recipients. Most local and systemic reactions were graded as mild to moderate and did not lead to hospitalization.
UNASSIGNED: The reactogenicity of the heterologous prime-boost with CoronaVac and mRNA-based COVID-19 vaccine booster among young adults is reassuring, and no unexpected concerns were identified.